New treatment option arrives for Canadians with sleep apnea and obesity – CTV
June 22, 2026
Health Canada has approved Zepbound (tirzepatide) as the first medication in Canada indicated for the treatment of moderate-to-severe obstructive sleep apnea (OSA) in adults living with obesity.
The approval marks a new development in the treatment of a condition that affects breathing during sleep and can contribute to a range of health complications, including cardiovascular disease, Type 2 diabetes and daytime fatigue. OSA occurs when the upper airway becomes blocked during sleep, causing repeated interruptions in breathing throughout the night.
The medication is approved for use alongside a reduced-calorie diet and increased physical activity in adults with a body mass index of 30 or higher.
For patients living with both obesity and sleep apnea, the relationship between the two conditions can be difficult to break, according to Dr. Paulette Pillersdorf, a dentist and snoring and sleep apnea therapist.
